Columbia Teams With Sanofi on Diabetes Research
France’s Sanofi-Aventis (NYSE:SNY) is tapping into the diabetes expertise at Columbia University Medical Center, signing a three-year deal with the college to investigate new diabetes treatments. According to a statement from Sanofi, the partnership will focus on a hormone called osteocalcin, which influences blood sugar and fat deposition. Columbia professor Gerard Karsenty, who chairs Columbia’s department of genetics and development, will lead the Sanofi partnership. In 2007, Karsenty (also a New York Xconomist), published a paper in the journal Cell in 2007 describing how the bone-forming cells known as osteoblasts produce osteocalcin-a discovery that the folks at Sanofi believe could open doors to new diabetes treatments.